Compare WLK & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLK | SYRE |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.5B |
| IPO Year | 2004 | 2015 |
| Metric | WLK | SYRE |
|---|---|---|
| Price | $75.70 | $90.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $106.87 | $85.08 |
| AVG Volume (30 Days) | ★ 1.0M | 868.0K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $11,170,000,000.00 | N/A |
| Revenue This Year | $5.51 | N/A |
| Revenue Next Year | $3.74 | N/A |
| P/E Ratio | $105.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.33 | $14.51 |
| 52 Week High | $124.23 | $110.18 |
| Indicator | WLK | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 36.08 |
| Support Level | $71.96 | $66.78 |
| Resistance Level | $79.81 | $106.10 |
| Average True Range (ATR) | 2.04 | 4.73 |
| MACD | -0.46 | -2.05 |
| Stochastic Oscillator | 20.67 | 7.21 |
Westlake is a forward-integrated commodity chemicals firm based in Houston. It began as a single low-density polyethylene plant and expanded its capabilities to include ethylene, vinyl chloride monomers, and polyvinyl chloride over the next two decades. The acquisition of Axiall in 2016 made it a North American leader in chlor-alkali and PVC. Today, Westlake has two defined segments: performance and essential materials, and housing and infrastructure products. The HIP segment began operating in 2022 following a series of acquisitions in the building products space. The firm aims to maximize the value of its chemical production by integrating with the HIP segment, realizing the higher margins of finished commercial goods.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.